POLE-Mutant Colon Cancer Treated with PD-1 Blockade Showing Clearance of Circulating Tumor DNA and Prolonged Disease-Free Interval

By sjmartinez • May 28, 2023

Bikhchandani M, Amersi F, Hendifar A, Gangi A, Osipov A, Zaghiyan K, Atkins K, Cho M, Aguirre F, Hazelett D, Alvarez R, Zhou L, Hitchins M, Gong J. POLE-Mutant Colon Cancer Treated with PD-1 Blockade Showing Clearance of Circulating Tumor DNA and Prolonged Disease-Free Interval. Genes (Basel). 2023 May 8;14(5):1054. doi: 10.3390/genes14051054. PMID: 37239414; PMCID: PMC10218075.

Tags: Cedars Sinai DoM, Checkpoint Inhibitor, Colon cancer, Hematology/Oncology, high tumor mutation burden, immunotherapy, MSS, POLE, Publications

Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trial

Lau G, Sangro B, Cheng AL, Kudo M, Kelley RK, Tak WY, Gasbarrini A, Reig M, Lim HY, Tougeron D, De Toni EN, Tam VC,[...]

How I do it: Best practices for right heart catheterization in the diagnosis of pulmonary hypertension

Matusov Y, Kolaitis NA, Geft D, DesJardin J, Barnett C, Hage A, De Marco T, Lewis MI. How I do it: Best practices for right[...]

Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement

Oprea AD, Ostapenko LJ, Sweitzer B, Selzer A, Irizarry-Alvarado JM, Hurtado Andrade MD, Mendez CE, Kelley KD, Stewart E, Fernandez Robles CR, Chadha RM, Camilleri[...]